Experts discuss the development of new directions for sugar electrolyte infusion

The Chinese Society for Parenteral and Enteral Nutrition (CSPEN) is a medical institution that promotes evidence-based application of parenteral enteral nutrition to provide patients and physicians with safe and beneficial nutritional guidelines. It is also a current development in China. The most powerful and authoritative nutritional academic group covering a number of clinical medicine departments.

In June this year, organized by the Chinese Society of Parenteral and Enteral Nutrition, organized by Nanjing General Hospital of the Nanjing Military Region, and organized by the First Affiliated Hospital of Zhengzhou University, the “2011 National Symposium on Parenteral Enteral Nutrition” was held in Zhengzhou International Convention and Exhibition Center. The number of participants reached more than 3,000. The conference focused on the topic of basic and clinical research in the field of parenteral nutrition support in various fields, and invited well-known experts at home and abroad to give lectures and academic exchanges.

The theme of the conference was "reasonable nutrition, better curative effect" and the content of clinical nutrition involved was very extensive. The topic of "glycemic control of inpatients" was particularly noticeable in many topics of the conference. As the problem of blood sugar in patients, especially the impact of blood glucose on the prognosis of patients, has increasingly attracted the attention and attention of clinical departments, the enthusiasm of participating participants in the discussion is very high. In particular, the symposium also used the microblog interaction of the audience and the lucky draw. It further stimulated everyone's thinking and exploration on the intervention of blood glucose in hospitalized patients.

At this special meeting, Professor Zhu Mingwei, deputy director of the Clinical Nutritional Therapy Branch of the Beijing Association of Chinese and Western Medicine, and the chief surgeon of the Department of General Surgery of the Beijing Hospital of the Ministry of Health believes that hyperglycemia is a common phenomenon in patients after surgery and will be long-term after surgery. Existence, which significantly affects the patient's prognosis, such as increasing the hospital infection rate, mortality, hospitalization time, etc., need to intervene in the patient's blood glucose status within a certain period of time. The measures for reasonable blood glucose intervention after surgery include reduction and prevention of insulin resistance, screening for nutritional risk, rational choice of parenteral enteral nutrition, and sugar infusion. Regarding the choice of sugar infusion for postoperative patients, Professor Zhu believes that the single use of traditional glucose and glucose electrolyte injections can no longer meet the clinical needs for blood glucose intervention, fructose injection, mixed sugar electrolyte injection, etc. The emergence of a new type of sugar infusion should be well compensated for the lack of energy supply of glucose and glucose electrolyte infusion, fluctuations in blood glucose, incomplete rehydration and so on. This view of him was also recognized and supported by Prof. Li Ning, the chairman of the Chinese Society of Parenteral Nutrition, and Professor Wei Junmin, vice chairman of the Chinese Society of Intestinal Nutrition.

“This special meeting can be successfully held in the highest academic event in China's nutrition industry. There are so many clinical experts and doctors actively participating in and discussing. The new sugar infusion can be recognized by a large number of domestic authorities in the field of clinical nutrition. I feel very much. This shows that with the development of clinical medicine, especially clinical nutrition medicine, clinically more and more differentiated products are needed to meet the needs of patients with different rehydration energy supplies; this also means that after 5 to 6 years After the professional academic promotion, the image of Zhengda Fenghai as a professional brand new sugar infusion brand has established a firm foothold in the clinical nutrition field and has a promising market.” Executive Vice President, Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. Mr. Zhu Yong said after the meeting.

Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. is a joint venture specializing in the production of new sugar infusions. Its main products include Fenghaineng Fructose Injection, Fenghaiping Fructose Sodium Chloride Injection, Xinhaineng Mixed Sugar Electrolyte Injection, etc. New sugar infusion brand. At present, in the hospital's solvent infusion market, Fenghai Fructose Injection ranks the first place in the market for new sugar infusions, and has entered the national Medicare drug directory; the company's flagship product in the fluid supply market is Xinhai. The ability to mix sugar electrolyte injections also showed a burst of growth, quickly filling the gaps in high-end products in the market.